Home » Market News » DirectorsTalk Highlights » Is your organisation ready for the ICH E9 (R1) regulatory updates
Open Orphan PLC

Is your organisation ready for the ICH E9 (R1) regulatory updates

How will this impact your development programs from a regulatory perspective. Get updates on the FDA guidance on Demonstrating Substantial Effectiveness and on Adaptive Trial Designs for clinical trials.

Venn Sciences’ Francois Aubin provides insights on the history, purpose/scope and the framework around these changes.

Open Orphan (LON:ORPH) was founded in 2017, with the goal of rapidly building Europe’s leading pharma services company by a management team with extensive industry and financial expertise. The company comprises of two commercial specialist CRO services businesses (Venn Life Sciences and hVIVO) and is also developing a genomics data platform business (Genomic Health Data). 

To read the full news article please click here

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.